Benchling – the cloud R&D powering the biotechnology industry – launches a new whitepaper in partnership with AstraZeneca, exploring how AstraZeneca has become the first company to recycle critical DNA constructs at scale, reducing the cost of creating DNA constructs by 80-90%.

The whitepaper explores how AstraZeneca’s combined team of computational and molecular biologists, along with Benchling, have created the FRAGLER (FRAGment recycLER), a novel solution for the whole DNA synthesis industry, and one that is open-sourced, available now on GitHub.

DNA constructs are vital to kick-start drug development, but the time and cost of producing them can significantly delay or even halt treatments getting to market – something that became particularly evident during the COVID-19 pandemic. For biotech’s to be able to innovate and drive scientific discoveries, they need the ability develop DNA sequences with flexibility and at scale – and this is what AstraZeneca and Benchling have addressed.

By integrating FRAGLER into Benchling, AstraZeneca has been able to accelerate its approach to deliver an industry-leading automated lab ecosystem. Through increased efficiency, it’s possible for DNA construction to take just 3 weeks, compared to 4-8 weeks typically, and deliver cost savings from 50 to 90%.

View whitepaper